Press

Otsuka Pharmaceutical to Acquire Mindset Pharma

Aug 31 • 7 min read

Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset“), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, announced that they have entered into a definitive arrangement agreement (the “Agreement“) pursuant to which Otsuka Pharmaceutical Co., Ltd. (“Otsuka“), through its wholly- owned subsidiary…

MAPS Launches Online Video Sessions from Psychedelic Science 2023 with The Virtual Trip

Aug 31 • 3 min read

The Multidisciplinary Association for Psychedelic Studies (MAPS) has begun publishing a collection of content from the highly acclaimed Psychedelic Science 2023 conference. PS2023: The Virtual Trip brings the world’s leading experts in psychedelic research, therapies, policy, culture, and business to the general public through an affordable and accessible online platform. Set the Setting, the first compilation of videos from…

Mydecine Announces Conditional Approval of CSE Listing

Aug 31 • 2 min read

Mydecine Innovations Group Inc. (NEO:MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), is pleased to announce that it has made an application and received conditional approval to list its common shares on the Canadian Securities Exchange (the “CSE”) subject to fulfilling customary CSE requirements. The Company anticipates that trading will commence immediately upon receipt…

Oscillate Interim Loss Widens Amid Increased Investment Loss

Aug 30 • 1 min read

Oscillate PLC – investor in companies in medical psychedelics industry – Publishes interim results a day after it reported that shareholders at the annual general meeting rejected placing company into members voluntary liquidation. Loss in the six months to May 31 widens 46% to GBP508,310 from GBP348,033 a year prior. Loss on investments at fair…

COMPASS Pathways To Participate in Upcoming September Investor Conferences

Aug 30 • 3 min read

COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in the following investor conferences: Live audio webcasts of the fireside chats at the HC Wainwright and Cantor conferences will be accessible from the “Events” page of the “Investors” section…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441